Multi-Gene AAV Vectors to Limit Dopaminergic Neuron Degeneration
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Current gene therapies for central nervous system degeneration, particularly Parkinson's Disease, have shown limited success in treating and preventing the degeneration of dopaminergic neurons.
Innovation Solution
The use of recombinant gene therapy vectors and gene editing systems targeting PARK2, PINK1, DJ-1, LRRK2, SCNA, c-Rel, ATG7, VMAT2, and GBA genes, or their functional fragments, to express wild-type proteins in neurons, combined with AAV vectors for delivery, to inhibit neuron degeneration and promote dopamine production.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Reliability
If conventional gene therapy approaches are used for Parkinson's Disease, then some therapeutic effect is achieved, but the treatment shows limited success in preventing dopaminergic neuron degeneration
Solution Approach 1:
The invention divides the therapeutic approach into multiple targeted gene delivery systems, each addressing specific pathological mechanisms (alpha-synuclein aggregation, mitochondrial dysfunction, lysosomal impairment) rather than using a single generalistic therapy, thereby improving overall treatment reliability and preventive capacity
Solution Approach 2:
The invention modifies key parameters of gene therapy by selecting specific genes (PARK2, PINK1, DJ-1, LRRK2, GBA) and their expression levels to target multiple pathological parameters simultaneously, transforming the therapy from limited effectiveness to comprehensive disease modification
2Adaptability or versatility
If multiple genes are targeted simultaneously, then comprehensive disease coverage is improved, but the complexity of the therapy increases
Solution Approach 1:
The invention creates a multi-functional gene therapy system where multiple genes (PARK2, PINK1, DJ-1, LRRK2, GBA) are delivered through a unified approach using AAV vectors, allowing single administration to address multiple pathological mechanisms simultaneously, thereby achieving comprehensive disease coverage without proportionally increasing procedural complexity
Solution Approach 2:
The invention uses adeno-associated virus (AAV) vectors as intermediary carriers to deliver multiple therapeutic genes into neurons, simplifying the delivery mechanism while achieving complex multi-gene therapy goals, thus managing therapy complexity while maintaining versatile disease coverage
Data Source
AI summary
The present disclosure relates generally to compositions and methods for treating, preventing, inhibiting, or delaying central nervous system degeneration. The disclosure relates to a recombinant gene therapy vector comprising a PARK2, PINK1, DJ-1, LRRK2, SCNA, c-Rel, ATG7, VMAT2, or GBA gene, or functional fragment or variant thereof. The disclosure also relates to CRISPR/Cas-based gene editing systems for treating, preventing, inhibiting, or delaying central nervous system degeneration.